Glenmark Generics (Europe) Limited (GGEL) has launched the first generic of Atovaquone Proguanil in the UK following the revocation of the Malarone patent in the High Court in the UK.

Judgement has been handed down in the case of Glenmark Generics (Europe) Limited and Generics [UK] Limited t/a Mylan v The Wellcome Foundation & Glaxo Group Limited. The case involved the revocation of Glaxo’s patent for its anti-malarial product Malarone. Following proceedings in the High Court, Justice Arnold revoked Glaxo’s patent on the basis that it was obvious.

Atovaquone Proguanil is indicated for the prophylaxis and treatment of acute, uncomplicated p.falciparum malaria particularly where there is likely to be resistance. Based on IMS Health sales data for the 12 month period ending September 2012, Atovaquone Proguanil garnered sales of Euro 20.69 million in the UK.

Glenmark Generics (Europe) Limited is part of Glenmark Generics Limited. The European arm is headquartered in the UK and operates through its own entities and distribution partners in the UK, Germany, the Netherlands, Denmark, Sweden and Ireland.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader.